Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focusing on rare diseases and multi-drug resistant (MDR) bacterial infections, has announced its upcoming second quarter 2024 financial results and business update. The company will host a conference call and live audio webcast on Monday, August 5th, 2024, at 4:30 p.m. ET.

Investors and interested parties can access the call by dialing 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and referring to conference ID 13747505. Alternatively, they can request a return call or access the live audio webcast through the provided link. The webcast will also be available on Spero's Investor Relations webpage and archived for 30 days following the call.

07/29/2024 - 04:05 PM

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5^th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.

To access the call, please dial 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and refer to conference ID 13747505, or click on this link and request a return call. The audio webcast can be accessed live on this link and also on the “Investor Relations” page of the Spero Corporate Website at https://sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information - www.sperotherapeutics.com

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries:
media@sperotherapeutics.com

FAQ

When will Spero Therapeutics (SPRO) report its Q2 2024 financial results?

Spero Therapeutics (SPRO) will report its second quarter 2024 financial results on Monday, August 5th, 2024, at 4:30 p.m. ET during a conference call and live audio webcast.

How can investors access Spero Therapeutics' (SPRO) Q2 2024 earnings call?

Investors can access Spero Therapeutics' (SPRO) Q2 2024 earnings call by dialing 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and referring to conference ID 13747505. Alternatively, they can access the live audio webcast through the provided link or the company's Investor Relations webpage.

What is the focus of Spero Therapeutics (SPRO)?

Spero Therapeutics (SPRO) is a multi-asset clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections.

Will Spero Therapeutics (SPRO) provide a business update during the Q2 2024 earnings call?

Yes, Spero Therapeutics (SPRO) will provide a business update along with its financial results during the conference call and webcast on August 5th, 2024.